Show Summary Details
Page of

Selection of patients for endocrine therapies 

Selection of patients for endocrine therapies
Selection of patients for endocrine therapies

W. Fraser Symmans

and Lajos Pusztai

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 June 2020

Diagnostic tests that target the presence of oestrogen receptor (ER) expression or activity are used to deter-mine a patient’s eligibility for endocrine therapies.

It is appropriate to test in situ, invasive, or recurrent breast cancer for ER expression or activity to select patients for preventative, adjuvant, or palliative endocrine therapies.

Current tests accurately exclude eligibility for endocrine therapies, but have only modest positive predictive value.

Novel multiplex molecular assays have demonstrated considerable potential to further refine the selection of patients for endocrine therapies.

Future tests could discriminate between different clinical treatment options.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.